Shivani Kamat, MD
Glaucoma Specialist · Dallas, TXNPI 1326368549
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $112,792 of the $163,651 with a category attached, or 68.9%. 13 manufacturers reported payments, led by AbbVie at 41.7% of the total. 2025 is the largest year on record at $91,319, more than ten times the $123 reported in 2019. Among glaucoma specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $624.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Glaukos Corporation$36K
- Nova Eye, Inc.$19K
- Alcon$15K
- Bausch & Lomb Americas Inc.$12K
- Alcon Research LLC$7K
- plus $6K from 7 others
Across 30 payments — averaging $4999.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$150K
What the payments were for
- Consulting fees$112,79269%
- Speaking & faculty fees$31,40019%
- Travel & lodging$9,2016%
- Food & beverage$10,2586%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $68,316 |
| Glaukos Corporation | 47 | $35,665 |
| Nova Eye, Inc. | 7 | $19,388 |
| Alcon | 29 | $15,399 |
| Bausch & Lomb Americas Inc. | 21 | $11,626 |
| Alcon Research LLC | 2 | $7,240 |
| NEW World Medical,inc. | 17 | $5,089 |
| Aerie Pharmaceuticals, Inc. | 5 | $693 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $128 |
| Sight Sciences, Inc. | 2 | $32 |
| Dompe US, Inc. | 1 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$42,428
- DURYSTA$16,801
- Travoprost Intraocular Implant - iDose$15,268
- Hydrus Microstent$12,279
- Rocklatan$7,482
- Rhopressa$7,350
- Kahook Dual Blade$4,493
- Ahmed Glaucoma Valve$4,493
- LUMIGAN$4,056
- Clearpath$3,893
- Streamline$3,893
- VYZULTA$2,433
- iDose$2,375
- iStent inject W$1,649
- Via360$1,393
- iDoseTR$733
- Streamline Surgical System$600
- iStent Infinite$560
- Radius XR$371
- IACCESS$345
How this compares
$163,651 in reported general payments places this provider in the 95th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 202 | $106,619 |
| VyzultaLatanoprostene Bunod | 97 | $52,955 |
| RhopressaNetarsudil Mesylate | 96 | $48,114 |
| CombiganBrimonidine Tartrate/Timolol | 96 | $41,883 |
| RocklatanNetarsudil Mesylat/Latanoprost | 94 | $40,783 |
| Alphagan PBrimonidine Tartrate | 98 | $39,808 |
| Brimonidine Tartrate | 702 | $32,104 |
| RestasisCyclosporine | 42 | $29,782 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,234 | $21,736 |
| Latanoprost | 2,179 | $19,563 |
| Travoprost | 123 | $17,336 |
| XiidraLifitegrast | 18 | $17,271 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 58 | $16,259 |
| Methazolamide | 85 | $15,705 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 85 | $10,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $68,316 | $218,093438 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $693 | $88,896190 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $11,626 | $70,226115 claims |
| AlconSimbrinza | $15,399 | $16,25958 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $23 | $2,35518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Dallas
- Karanjit KoonerDallas$3K
- Clifford GoodrichDallas$958
- Jess WhitsonDallas$923
- Mugen LiuDallas$677
- Robert FeldmanHouston$31K
- Amenze OriaifoAustin$18K
- David LeeHouston$17K
- Nicholas GurneyFt Worth$13K
- Patrick WuHouston$11K
- Irina VoloskoAustin$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.